The 2018 Paediatric HIV Stakeholder’s Meeting brings together key partners of DNDi to discuss vital issues concerning access to ART adapted to the needs of infants and young children living with HIV, their families, and their caregivers.
Opening
Date: Wednesday, 3 October 2018
Time: 09:00-09:20
Venue: Speke Resort, Munyonyo, Kampala, Uganda
| Opening speech and meeting objectives | François Bompart, Director of Paediatric HIV/HCV Programmes, DNDi, Switzerland
Sara Padidar, Programme Officer, Unitaid |
Panel discussions
New treatments for children living with HIV: DNDi’s journey so far
Time: 09:20-10:30
Chair: François Bompart, Director of Paediatric HIV/HCV Programmes, DNDi, Switzerland
| Update on DNDi’s paediatric HIV programme Isabelle Andrieux-Meyer, Head of Clinical Development Paediatric HIV/HCV Programmes, DNDi, Switzerland |
| Pharmaceutical development of LPV/r-based formulations to meet the needs of infants and children: what lessons have we learned? Jean-René Kiechel, Expert in R&D (FACT & HIV), DNDi, Switzerland |
Front-line experience from clinical study and programmatic implementation
Time: 11:00-12:30
Chairs: Adeodata Kekitiinwa, Executive Director, Baylor College, Uganda & Mastidia Rutaihwa, National AIDS Control Program, Ministry of Health, Tanzania
| LIVING study experience from the investigators: what have we learned in Kenya, Uganda and Tanzania Caren Mburu, Kenyatta Hospital, Kenya Kathy Kyakwera, MSF/Epicentre, Uganda Nzovu Ulenga, Director, Health Systems Strengthening and Strategic Information, Management and Development for Health (MDH), Tanzania |
| Uptake of LPV/r-based formulations (syrup and pellets) in children: experience from Kenya and Uganda Laura Oyiengo, Pediatric and Adolescent HIV Program Manager, Ministry of Health, Kenya & Cordelia Katureebe, Head of Delegation, Ministry of Health, Uganda |
Looking forward – Access
Time: 13:30-15:10
Chair: Olawale Salami, Paediatric HIV Clinical Project Manager, DNDi Africa, Kenya
| An update on the pharmacokinetic and safety study of the 4-in-1 formulation Victor Musiime, Senior Lecturer at Makerere University, College of Health Sciences, Department of Paediatrics and Child Health, Uganda |
| New WHO treatment guidelines for children living with HIV and implications for programme implementation Elizabeth Obimbo, Department of Paediatrics & Child Health, School of Medicine, University of Nairobi & Consultant Pediatrician, Kenyatta National Hospital, Kenya |
| The role of civil society in spearheading advocacy for better treatment options in children living with HIV Proscovia Namakula, Global Coalition of Women Against AIDS, Uganda |
Open discussion
What are the key considerations in ensuring access to child-adapted ARV formulations in 2019 and beyond?
Time: 15:30-16:00
Chair: Olawale Salami, Paediatric HIV Clinical Project Manager, DNDi Africa, Kenya
More information:
